OSTEOproDENT—Research and Development of an Advanced Formulation for Alveolar Ridge Augmentation—is a collaborative initiative led by Sartorius Croatia – Libra Elektronik d.o.o. in partnership with Genera Research, the University of Zagreb School of Medicine, and Dental Office Bekavac. The project kicked off on January 13, 2025, and is projected to run through January 12, 2028, with a total budget of €4.67 million (€2.7 million in EU co‑financing)
Genera Research Ltd., a Croatian biotech company and pioneer in bone regeneration, is growing its expert team to support the implementation of our OSTEOforUNION and OSTEOproDENT projects — a groundbreaking initiative focused on the clinical-grade production of rhBMP6, the active substance in our novel biologic drug OSTEOGROW, designed to regenerate bone tissue.
We seek 2 Biotechnology Engineers ready to work hands-on in GMP manufacturing biological substances using CHO cell cultures, Biostat RM bioreactors, MyCap systems, and FPLC/HPLC chromatography techniques.
We actively recruit highly motivated professionals across multiple disciplines as we scale up GMP manufacturing, regulatory operations, clinical trials, and commercial readiness. We seek individuals who are not only technically qualified but also deeply committed to innovation, compliance, and improving patients’ lives through cutting-edge science.
Genera Research is proud to announce a significant milestone in the world of regenerative medicine with the successful recruitment of the first patient in Phase II of a clinical study. This study is focused on testing the efficacy, safety, and tolerability of Osteogrow (recombinant human bone morphogenetic protein 6 in autologous blood coagulum) in alveolar ridge regeneration following tooth extraction. The clinical site for this groundbreaking study is the prestigious Stomatology Faculty of the University of Zagreb.
In medical breakthroughs, the OSTEOproSPINE project, with Genera Research as a clinical trials sponsor and a consortium partner, has been spotlighted by CORDIS in the ‘Results in Brief’ section of the European Commission’s website. This recognition underscores the significant strides in developing Osteogrow, a novel treatment promising to revolutionize bone regeneration and relieve millions suffering from chronic lumbar back pain in the EU. The phase II clinical trial, backed by Genera Research, has shown that Osteogrow can effectively stabilize the lumbar spine and mitigate pain recurrence. Such innovative advancements exemplify our commitment to pioneering drug discovery and development. As we progress with the final Phase III clinical trials, we are inspired by the CORDIS selection to continue our mission of delivering life-changing treatments to the market. The anticipated introduction of Osteogrow-C in the EU market by 2028 is set to substantially impact patients' quality of life, making a significant milestone for Genera Research and the medical community at large.
The Symposium on Regenerative Medicine - New Platforms and Potentials, hosted by the Center of Excellence for Reproductive and Regenerative Medicine (CERRM) – Subunit for Regenerative Medicine, took place at the Amadria Park Hotel Royal in Opatija from October 23-25, 2023. This event was a collaborative effort, with Genera Research as a partner, featuring guest lecturers from its esteemed team.
On 25.10.2022 Genera Research COO Dora Adanić had the privilege to be a guest lecturer at Libertas International University in Zagreb on the Technology and Innovation Management course under the guidance of doc. Dr.sc. Helena Šlogar. The lecture topic was "Development and clinical testing of Osteogrow, the first Croatian drug for global use".
Genera Research was one of the sponsors of the 13th International BMP Conference 2022 held in Dubrovnik, Croatia, from the 8th to the 12th of October.
On June 19th, 2018 at the “Let the Stars Shine” exhibition in the European Parliament in Brussels project OSTEOGROW, coordinated by the University of Zagreb School of Medicine, was presented as one of five most significant Croatian projects financed by the European Union.
After the common cold, it is the second most common medical condition, and in more severe cases, surgery is usually perfomed.
The University of Zagreb School of Medicine is the head of the OsteoProSpine project, in which 12 partner institutions from six countries participate.
The drug OSTEOGROW is the first innovative drug in independent Croatia and the second after the very successful Sumamed, which is entirely the product of Croatian scientists. A little blood, a little bone protein and here is a medicine for bone regeneration and healing! The Croatian sensation of world scale in pharmaceuticals is called OSTEOGROW, and the results of the clinical trials conducted so far say that the first drug created in the Croatian state could become an indispensable aid to patients with bone healing problems and those who need to replace a missing part of the bone already in two to three years.